GSK vs AZN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Apr 02, 2026

GSK

60.9
AI Score
VS
GSK Wins

AZN

60.4
AI Score

Investment Advisor Scores

GSK

61score
Recommendation
BUY

AZN

60score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK AZN Winner
Forward P/E 8.4388 16.0772 GSK
PEG Ratio 0.4986 0.9506 GSK
Revenue Growth 6.2% 4.1% GSK
Earnings Growth 54.7% 53.9% GSK
Tradestie Score 60.9/100 60.4/100 GSK
Profit Margin 17.5% 17.4% GSK
Beta 1.00 1.00 Tie
AI Recommendation BUY BUY Tie

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.